BioXell S.p.A. announces change in management
BioXell S.p.A. announced that Enrico Colli, Chief Medical Officer, has resigned from the Company for personal reasons in order to pursue a career at a large pharmaceutical organization. He is expected to leave the Company at the end of September. Francesco Sinigaglia, Chief Executive Officer, will take over the responsibility for his function on an interim basis until a successor is appointed.
"Enrico Colli has contributed significantly to the successful development of our Company since he joined BioXell in 2002" commented Francesco Sinigaglia. "I would like to acknowledge the excellent work Enrico has done in setting up the clinical programs for Elocalcitol, our lead compound. Today, Elocalcitol has the potential to become the monotherapy of choice for the treatment of lower urinary tract symptoms (LUTS) and could target a significant portion of both, the OAB and BPH markets. We all wish Enrico well in his future endeavors."
Other news from the department people
